Publications
Dec 9, 2024
PreciseBreast, an AI-enabled digital test predicting breast cancer recurrence is equivalent with Oncotype
See More
Dec 9, 2024
PreciseBreast, an AI-enabled digital test predicting breast cancer recurrence is equivalent with Oncotype
See More
Press Releases
Dec 9, 2024
Study Results from COTA, PreciseDx, and Baptist Health South Florida Confirm Novel AI Test, PreciseBreast is Equivalent to Oncotype DX at Predicting Breast Cancer Recurrence
See More
Dec 9, 2024
Study Results from COTA, PreciseDx, and Baptist Health South Florida Confirm Novel AI Test, PreciseBreast is Equivalent to Oncotype DX at Predicting Breast Cancer Recurrence
See More
Media Coverage
Dec 6, 2024
MedTech PreciseDx's digital pathology AI on par with genomic testing in predicting breast cancer recurrence risks: study
See More
Dec 6, 2024
MedTech PreciseDx's digital pathology AI on par with genomic testing in predicting breast cancer recurrence risks: study
See More
Press Releases
Nov 20, 2024
PreciseDx Announces Formation of Scientific Advisory Board
See More
Nov 20, 2024
PreciseDx Announces Formation of Scientific Advisory Board
See More
Media Coverage
Aug 22, 2024
PreciseDx raises $20.7M in series B funding
See More
Aug 22, 2024
PreciseDx raises $20.7M in series B funding
See More
Media Coverage
Aug 22, 2024
PreciseDx Raises $20.7M Series B
See More
Aug 22, 2024
PreciseDx Raises $20.7M Series B
See More
Media Coverage
Aug 22, 2024
Start-up raises US$20.7m to ‘advance’ AI-based cancer risk assessments
See More
Aug 22, 2024
Start-up raises US$20.7m to ‘advance’ AI-based cancer risk assessments
See More
Media Coverage
Aug 21, 2024
PreciseDx picks up $20.7M to advance AI-based breast cancer risk assessment
See More
Aug 21, 2024
PreciseDx picks up $20.7M to advance AI-based breast cancer risk assessment
See More
No results.
Contact us today to learn more about PreciseBreast.
